Physician profile
James W Steiner
NPI 1457369464
$12,020.72
in general payments reported to CMS, 2019-2025
35 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $960 · 2021: $1,861 · 2022: $1,838 · 2023: $2,027 · 2024: $2,420 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,016.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,237.12 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,873.27 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,216.20 | 2019-2024 | Spravato |
| Novo Nordisk INC | $1,192.71 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $716.61 | 2022-2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $567.95 | 2019-2025 | |
| Abbvie INC. | $428.93 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $386.56 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.04 | 2021-2024 | Xifaxan, Trulance |
| Pfizer INC. | $287.10 | 2019-2025 | |
| Axsome Therapeutics, INC. | $272.66 | 2024-2025 | Symbravo, Auvelity |
| Lilly USA, LLC | $258.58 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.00 | 2019-2024 | Jardiance |
| Impactortho, INC. | $151.26 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $135.60 | 2025 | Austedo Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medartis INC. | $111.49 | 2020 | |
| Merck Sharp & Dohme LLC | $104.88 | 2020 | |
| Amarin Pharma, INC. | $103.02 | 2020-2022 | |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $49.23 | 2020-2021 | |
| Allergan, INC. | $40.82 | 2020 | |
| Medicure Pharma INC. | $33.65 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.73 | 2022 | |
| Cleerly, INC. | $26.76 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Axonics, INC. | $25.68 | 2023 | Axonics |
| Radius Health, INC. | $25.14 | 2024 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $22.14 | 2023 | Trintellix |
| Esperion Therapeutics, INC. | $20.76 | 2025 | Nexletol |
| Intra-Sana Laboratories | $20.49 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Abbott Laboratories | $20.09 | 2025 | Proclaim |
| Corcept Therapeutics | $18.94 | 2025 | Korlym |
| Daiichi Sankyo INC. | $17.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.79 | 2021 | |
| Bardy Diagnostics, INC. | $15.75 | 2021 | |
| Sanofi Pasteur INC. | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.